U.S. flag
        An official website of the United States government
          Here’s how you know

      Official websites use .gov
                A
                .gov
                website belongs to an official government organization in the United States.
          Secure .gov websites use HTTPS
                A lock
                  (
                  
                  )
                   or
                  https://
                   means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.Search
                Menu
    
                      Información en Español
                      Search NINDSSearch NINDS
            

            Main navigation
  

        
              Health Information
                                     Toggle Health Information Dropdown
                                Disorders
                Clinical Trials
                Patient & Caregiver Education
                Public Education
                Support Resources
                Funding
                                     Toggle Funding Dropdown
                                Find Funding Opportunities
                About Funding
                Preparing Your Application
                After You Submit
                Determining Your Funding Likelihood
                Manage Your Award
                NINDS Small Business Program
                Training & Career Development
                Current Research
                                     Toggle Current Research Dropdown
                                Coronavirus and NINDS
                Focus on Disorders
                Focus on Tools & Topics
                Research Funded by NINDS
                Research at NINDS
                Scientific Resources
                Trans-Agency Activities
                News & Events
                                     Toggle News & Events Dropdown
                                Events
                News
                Director's Messages
                About NINDS
                                     Toggle About NINDS Dropdown
                                Who We Are
                What We Do
                Job Opportunities 
 Home
                                Current Research
                        Research Funded by NINDS
                        Translational Research
                        Innovation Grants to Nurture Initial Translational Efforts (IGNITE Program)
SHARE: IGNITE Milestone Examples
Milestones should be composed of three basic components: 1) Desired goal, 2) Timeline or decision point by which the goal must be accomplished, and 3) Evidence that the goal has been accomplished based upon quantitative criteria.


  
**Disclaimer: The examples shown below are for illustrative purposes ONLY. NINDS is not endorsing particular development plans or models, parameters, or cut-off values for any disease, modality, or stage of development. Therefore, NINDS expects Investigators to establish milestones that are scientifically appropriate and justified for the application.**

**PAR-21-122**: IGNITE Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed).

The R61 phase is for assay (efficacy and PD) planning, preparation and refinement, whereas the R33 phase is for implementation of efficacy or PD studies.  Achievement of the milestone should demonstrate that the study workflow is planned and that all assays (efficacy and PD) are ready for compound or biologic testing during the R33 phase.  One or more milestones must be proposed.  Some examples include:

1. Efficacy assays are ready for compound or biologic testing at the time of transition to the R33 phase, according to the following criteria:

a. Positive controls show a statistically significant and dose-dependent effect relative to the negative control on the efficacy endpoint measure, where the study design included appropriate randomization and blinding procedures, with power ≥ 80%
b. The effects of positive controls on the endpoint measure can be attenuated by ≥ 70% with a test agent (e.g., target-specific antagonist/antibody/siRNA/gene vector, etc.) in a dose-dependent manner.

2. Pharmacodynamic (PD) measures are ready for compound or biologic testing at the time of transition to the R33 phase, according to the following criteria:

a. Positive controls show a statistically significant and dose-dependent effect relative to the negative control on the PD measure, where the study design included appropriate randomization and blinding procedures, with power ≥ 80%
b. The effects of positive controls on the PD measure can be attenuated by ≥ 70% with a test agent (e.g., target-specific antagonist/antibody/siRNA/gene vector, etc.) in a dose-dependent manner
c. Positive controls alter the activity of signaling molecules immediately proximal to the therapeutic target, and an antagonist, siRNA, gene vector, etc. attenuates this effect.  Antagonists, siRNA, antibodies, etc. do not attenuate non-specific activation of the target
d. The PD measure shows the required dynamic range (high-low value), precision (%) and sensitivity (lowest reliable value) for the assay in question.

3. Compounds and biologics to be tested have been characterized for biophysical or physico-chemical characteristics and demonstrate properties appropriate for the reliable interpretation of efficacy and PD testing at the time of transition to the R33 phase. These characteristics include:

a. Pharmacokinetic characteristics (t1/2≥ X, Cmax≥ X, AUC ≥ X, brain:plasma ≥ X, oral bioavailability ≥ X) that would allow sufficient systemic and brain exposure to provide a concentration ≥ 2x IC50 at the site of action during the time of testing, or preliminary viral vector or cell distribution
b. Biophysical/physicochemical characteristics that would allow reliable interpretation of efficacy and PD data:

i. Purity of protein produced in E.coli  > 95% via SDS-PAGE or SEC-HPLC
ii. Purity of protein 88% via RP-HPLC with no more than 12% total product-related impurities
iii. Identity of protein or gene vector established by Western blot or dot blot
iv. Purity of small molecule > 95% via LC/MS
v. Solubility ≥ Xmg/mL, formulation feasible for test species at Xml/kg.

**PAR-21-123**: IGNITE Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed).

The R61 phase will support initial development and optimization of the animal model or ex vivo system and will include a set of clear and quantitative milestones as indicators of feasibility. After completion of this phase, the project may advance to the R33 phase for any required scaling, along with completion of internal and external validation studies. One or more milestones must be proposed.  Some examples include:

1. Gene expression verified (X-fold change, resulting in X-fold change in protein) and breeding efficiency sufficient for external validation activities in the R33 phase (assuming a requirement of N animals per study/3 months)

2. Endpoints reflecting disease and/or therapeutic intervention provide sufficient reproducibility and dynamic range for use in the drug discovery process.

a. Reliability: Mean data values are within X% of each other in two or more separate runs of the assay.  Alternatively, mean data values obtained in two separate assays show significant correlation (0.7-1.0).

b. Dynamic range: The floor and ceiling of the assay are separated by at X standard deviations from the mean.

**PAR-21-124**: IGNITE Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed).

The R61 phase is for assay development/feasibility and the R33 phase is for implementation of iterative screening.  Achievement of the milestone should demonstrate that the phase 1 is completed and that the project is ready for the R33 phase. One or more milestones must be proposed. Some examples include:

1. Developed assays will perform with the specificity and activity required for use as a compound or biologic screening method at the time of transition to the R33 phase. Activity will be demonstrated by the following:

a. The positive control inhibits enzyme activity by > 80%
b. The negative control, does not inhibit enzyme activity (< 5%)
c. Receptor negative cells do not respond to the positive control (< 5%).

2. Developed assays will perform with the signal-to-noise, precision and dynamic range required for use as a compound or biologic screening method at the time of transition to the R33 phase. Signal-to-noise, precision and dynamic range will be demonstrated by the following:

a. The Z’ score will be  ≥ 0.5, based on values from at least half a plate of positive and negative controls
b. The blinded test-retest reliability (r2 ) will be ≤ 0.75 on at least 4 positive and 4 negative compounds
c. The positive control demonstrates a dose-response relationship.

3. Developed assays will perform with the accuracy and precision required for use as a compound or biologic screening method at the time of transition to the R33 phase.  The reported accuracy and precision of the assay will be within 10% of a designated reference standard. Current Research
  
    

    Coronavirus and NINDS
                                                              
                    
                                      COVID-19 News & Events
    
            Coronavirus and the Nervous System
    
            ResourcesFocus on Disorders
                                                              
                    
                                      Alzheimer's Disease and Related Dementias
                                                              
                    
                                      Frontotemporal Dementia (FTD)
    
            Lewy Body Dementia (LBD) Research
    
            Mixed-Etiology Dementias (MED) Research
    
            Vascular contributions to cognitive impairment and dementia (VCID)Amyotrophic Lateral Sclerosis
    
            Epilepsy Research
                                                              
                    
                                      Curing the Epilepsies: The Promise of Research
    
            Epilepsy Therapy Screening Program (ETSP)Pain Research
    
            Parkinson's Disease Research
                                                              
                    
                                      Parkinson's Disease: Challenges, Progress, and Promise
    
            Parkinson’s Disease Research Centers of ExcellenceSpinal Cord Injury Research
    
            Traumatic Brain Injury Research
                                                              
                    
                                      NIH Chronic Traumatic Encephalopathy Diagnosis ConferenceUndiagnosed Disease Network
        
  
              
    
            Focus on Tools & Topics
                                                              
                    
                                      Biomarkers Research
                                                              
                    
                                      Biomarker Program FAQs
    
            Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Biospecimen Resource Access Committee (ME/CFS BRAC)Health Disparities Research
    
            Focus on the Neural Exposome
    
            Neural Engineering Research
    
            Neuroethics
    
            Stem Cell Research
        
  
              
    
            Research Funded by NINDS
                                                              
                    
                                      Clinical Research
                                                              
                    
                                      Office of Global Health and Health Disparities
                                                              
                    
                                      HERN Initiative
    
            U.S.-Japan Brain Research Cooperative Program (BRCP)NeuroNEXT
                                                              
                    
                                      NeuroNEXT Clinical SitesNeuroscience Research
                                                              
                    
                                      Fundamental Neuroscience ResearchTranslational Research
                                                              
                    
                                      Active Projects for Partnering
    
            CREATE Bio
                                                              
                    
                                      CREATE Bio Application Support Library
    
            CREATE Bio Contract Resources/Consultants
    
            CREATE Bio Guidance DocumentsDTR Staff Publications about Programs
    
            Innovation Grants to Nurture Initial Translational Efforts (IGNITE Program)
                                                              
                    
                                      IGNITE - Definitions for Key Terms
    
            IGNITE Milestone ExamplesONETOX: Neural Exposome and Toxicology Programs
                                                              
                    
                                      The Neural Exposome
    
            Chemical Threats
    
            Chemical SafetyTranslational Devices
                                                              
                    
                                      Device Frequently Asked Questions
    
            Human Open Research Neural Engineering Technologies (HORNET) initiative
    
            Milestones for Translational Device Cooperative AgreementsUltra-rare Gene-based Therapy (URGenT) Network
                                                              
                    
                                      Current URGenT Projects
    
            URGenT External Consultant Board (ECB) Members
    
            URGenT Project Consultants & ContractsResearch at NINDS
                                                              
                    
                                      Blue Ribbon Panel Review of NINDS Intramural Research Program
                                                              
                    
                                      Blue Ribbon Panel Highlights
    
            Blue Ribbon Panel Roster
    
            Charge to the Blue Ribbon Panel
    
            Executive Summary of the NINDS Blue Ribbon Panel ReviewScientific Resources
                                                              
                    
                                      Animal Models
    
            Cell/Tissue/DNA
    
            Clinical and Translational Resources
    
            Gene ExpressionTrans-Agency Activities
                                                              
                    
                                      CounterACT Program
                                                              
                    
                                      CounterACT Contract Core Resources
    
            CounterACT Publications
    
            CounterACT Scientific Research Contacts
    
            Current CounterACT Researchers & Projects
    
            FDA Guidance Documents
    
            NIH CounterACT Researcher Honors and AwardsICARE: Interagency Collaborative to Advance Research in Epilepsy
    
            Interagency Research Coordinating Committees
    
            NINDS' Role in the HEAL Initiative
                                                              
                    
                                      Early Phase Pain Investigation Clinical Network (EPPIC-Net)
    
            Pain Therapeutics Development Program
    
            Preclinical Screening Platform for Pain (PSPP)Office of Emergency Care Research
                                                              
                    
                                      OECR Funded Awards
    
            Research Involving an Exception from Informed ConsentRigor & Transparency
                                                              
                    
                                      Initiative to Improve Education in the Principles of Rigorous Research
    
            Rigor Champions and Opportunities
                                                              
                    
                                      NINDS Sustainable Transformation of Institutional Research Rigor (STIRR) Initiative
    
            Rigor IconsRigor and Transparency Resources

Did you find the content you were looking for?
  Yes, I did find the content I was looking for



No, I did not find the content I was looking forPlease rate how easy it was to navigate the NINDS website
  Very easy to navigate



Easy to navigate



Neutral



Difficult to navigate



Very difficult to navigateThank you for letting us know! Any other feedback?Submit

This site is protected by reCAPTCHA and the Google Privacy Policyand Terms of Serviceapply.

      Last reviewed on May 23, 2023
        Contact Us
  

        
              Contact NINDS
                Visitor Information
        Related Sites
  

        
              Site Map
                National Institutes of Health
                Department of Health & Human Services
                USA.gov
        Policies
  

        
              Accessibility
                Freedom of Information Act
                Linking Policy
                Privacy Statement
                Vulnerability Disclosure Policy
Follow NINDS On Social Media
          
          National Institutes of Health (NIH)
          9000 Rockville Pike, Bethesda, MD, 20892